SUZHOU, China, May 14, 2021 -- Transcenta Holding Limited (Transcenta), a clinical stage global biotherapeutics company with fully-integrated capabilities in discovery, development and manufacturing of antibody-based therapeutics, today announced that the updated phase I clinical data on the safety and efficacy of MSB2311, a pH-dependent PD-L1 antibody, in Chinese patients with advanced solid tumors and hematological malignancies will be presented as an abstract online publication at the 57th American Society of Clinical Oncology (ASCO) Annual Meeting. The 2021 ASCO Annual Meeting will be held online from June 4th to June 8th EDT.

SUZHOU, China, April 21, 2021 -- Transcenta Holding Limited (Transcenta), a clinical stage global biotherapeutics company with fully-integrated capabilities in discovery, development and manufacturing of antibody-based therapeutics, today announced that it has received clearance of its IND for TST005 from US FDA for initiating Phase I clinical trial of its bi-functional anti-PD-L1/TGF-β antibody.

SUZHOU, China, April 19, 2021 -- Transcenta Holding Limited (Transcenta), a clinical stage global biotherapeutics company with fully-integrated capabilities in discovery, development and manufacturing of antibody-based therapeutics, today announced the first patient has been successfully dosed in Phase I clinical study of TST001, a humanized monoclonal antibody targeting human Claudin18.2 (CLDN18.2), in combination with CAPOX for the treatment of patients with first-line locally advanced unresectable or metastatic gastric cancer.

SUZHOU, China, April 16, 2021 -- Transcenta Holding Limited (Transcenta), a clinical stage global biotherapeutics company with fully-integrated capabilities in discovery, development and manufacturing of antibody-based therapeutics, presented preclinical data of TST005, a bi-functional anti-PD-L1 and TGF-β trap fusion protein, in a poster during the 2021 American Association for Cancer Research (AACR) Virtual Annual Meeting, being held from April 10th to 15th and May 17th to 21st.

SUZHOU, China, March 24, 2021 -- Transcenta Holding Limited (Transcenta), a clinical stage global biotherapeutics company with fully-integrated capabilities in discovery, development and manufacturing of antibody-based therapeutics, today announced the expansion of its senior management team by appointing Dr. Xichen Zhang as Senior Vice President of Manufacturing and Dr. Steven Yu as Senior Vice President of DMPK & Translational Science.

SUZHOU and HANGZHOU, China, March 17, 2021- Transcenta, a global biotherapeutics company with fully-integrated capabilities in discovery, development and manufacturing of antibody-based therapeutics, today announced a major breakthrough in its continuous perfusion cell culture platform by achieving volumetric productivity of > 6 g/L per day while maintaining process and product quality attributes in a state of control for a 4-week culture.